



Radius Health, Inc.
Investor Relations Department
950 Winter St, North Building 1st Floor
North Building 1st Floor
Waltham, MA 02451
United States

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: RDUS

| | |
|---------------|----------------------------|
| Last Trade: | 35.93 |
| Trade Time: | 4:00 PM ET Mar 16, 2018 |
| Change: | 0.54 (+1.526%) |
| Day Range | 35.30 - 36.36 |
| 52-Week Range | 24.66 - 49.16 |
| Volume | 592,340 |

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Radius is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases. Radius' lead product, TYMLOS (abaloparatide) Injection was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. Radius' Marketing Authorisation Application (MAA) for abaloparatide-SC for the treatment of postmenopausal women with osteoporosis is under regulatory review in Europe. The Radius c... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Mar 17, 2018

[Radius Health Presents Positive Data for the ACTIVEExtend BMD Responder Analysis for TYMLOS™ \(abaloparatide\) Injection at ENDO 2018 Annual Meeting](#)

Mar 12, 2018

[Radius Health to Present at ENDO 2018 Including Results of the ACTIVEExtend BMD Responder Analysis for TYMLOS™ \(abaloparatide\) Injection](#)

Mar 6, 2018

[Radius Health to Present at the Cowen 38th Annual Health Care Conference](#)

Mar 1, 2018

[Radius Health Reports Fourth Quarter and Full Year 2017 Financial and Operating Results and Provides Business Update](#)

Feb 14, 2018

[Radius Health to Announce Fourth Quarter and Full Year 2017 Financial Results, Host Conference Call and Live Webcast on March 1, 2018](#)

Financials [\[View all \]](#)

[Fourth Quarter Financial Results](#)

Mar 1, 2018

[Annual Report \(10-K\)](#)

Apr 21, 2017

[Proxy Statement \(DEF 14A\)](#)

Nov 2, 2017

[Quarterly Report \(10-Q\)](#)

Aug 4, 2017

[Quarterly Report \(10-Q\)](#)

May 2, 2017

[Quarterly Report \(10-Q\)](#)